Pharmacotyping of Pancreatic Patient-derived Organoids

Inclusion Criteria: * Signed informed consent * Histopathological confirmation of PDAC and planned standard first-line treatment prior to entering this study OR Patients suspected of primary locally advanced, non-metastatic PDAC based on cross-sectional imaging undergoing diagnostic standard of care (SOC) EUS-FNB procedure * Age \> 18 years and older * Life expectancy greater than 3 months * ECOG/WHO Performance Status (PS) 0-1 * Patients must have normal organ and marrow function as defined below: * White blood cell count (WBC) ≥ 3 x 10⁹/L * Platelet count ≥ 100 x 10⁹/L * Serum bilirubin ≤1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L) * PP ≥ 40 or INR ≤ 1.5 * Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 40 mL/min (using the Cockcroft-Gault formula) Exclusion Criteria: * Contraindications for nurse administered propofol sedation (NAPS) * Contraindications for EUS-FNB procedure